Due to scheduled maintenance work, this service may not be available on Monday January 22nd between 08.00 am and 9.00 am CEST.
To improve security and privacy, we are moving our web pages and services from HTTP to HTTPS. To give users of web services time to transition to HTTPS, we will support separate HTTP and HTTPS services until the end of 2017. From January 2018 most HTTP traffic will be automatically redirected to HTTPS. [more...] View this page in https
Amyloidogenic glycoprotein (A4 protein or APP) is an integral, glycosylated
membrane brain protein [1,2]. APP is associated with Alzheimer's disease (AD).
This responsibility stems from the fact that a small peptide (of 43 residues),
called the amyloid β protein, which is part of the sequence of A4, is the
major constituent of amyloid deposits in AD and in Down's syndrome. As shown
in the schematic representation below, the amyloid β protein both precedes
and forms part of the unique transmembrane region of A4.
'X': Transmembrane region.
'B': Position of the amyloid beta protein in A4.
The exact function of A4 protein is not yet known, but it has been suggested
that it mediates cell-cell interactions. The sequence of A4 from mammalian
species is well conserved and is also similar to that of other proteins:
Mammalian protein APLP2 (APPH) (YWK-II) (CDEI-binding protein) .
We have derived two patterns specific to these proteins, the first one is a
perfectly conserved octapeptide located in the beginning of the extracellular
domain; the second is a conserved octapeptide located at the C-terminal end of
the cytoplasmic domain.
December 2004 / Pattern and text revised.
PROSITE methods (with tools and information) covered by this documentation:
Dyrks T., Weidemann A., Multhaup G., Salbaum J.M., Lemaire H.-G., Kang J., Muller-Hill B., Masters C.L., Beyreuther K.
Identification, transmembrane orientation and biogenesis of the amyloid A4 precursor of Alzheimer's disease.
PROSITE is copyright. It is produced by the SIB Swiss Institute
Bioinformatics. There are no restrictions on its use by non-profit
institutions as long as its content is in no way modified. Usage by and
for commercial entities requires a license agreement. For information
about the licensing scheme send an email to
or see: prosite_license.html.